
Ryvu Therapeutics S.A.
WSE:RVU.WA
Overview | Financials
Company Name | Ryvu Therapeutics S.A. |
Symbol | RVU.WA |
Currency | PLN |
Price | 64.5 |
Market Cap | 1,490,987,934 |
Dividend Yield | 0% |
52-week-range | 49.2 - 72.4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc. |
Website | https://www.ryvu.com |
An error occurred while fetching data.
About Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD